Evidence map›Paper›PMID 35999568›Full record

ArticleArthritis research & therapy2022

Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS).

Yasuhiro Shimojima, Dai Kishida, Takanori Ichikawa, Takashi Kida, Nobuyuki Yajima, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa and 24 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 1 country.

Yasuhiro ShimojimaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan. yshimoji@shinshu-u.ac.jp.ORCID 0000-0001-7100-1121
Dai KishidaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Takanori IchikawaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Takashi KidaInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nobuyuki YajimaDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Satoshi OmuraInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Daiki NakagomiDepartment of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan.
Yoshiyuki AbeDepartment of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
Masatoshi KadoyaCenter for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
Naoho TakizawaDepartment of Rheumatology, Chubu Rosai Hospital, Nagoya, Japan.
Atsushi NomuraImmuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
Yuji KukidaDepartment of Rheumatology, Japanese Red Cross Society Kyoto Daini Hospital, Kyoto, Japan.
Naoya KondoDepartment of Nephrology, Kyoto Katsura Hospital, Kyoto, Japan.
Yasuhiko YamanoDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.
Takuya YanagidaDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Koji EndoDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
Shintaro HirataDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
Kiyoshi MatsuiDepartment of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, Japan.
Tohru TakeuchiDepartment of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
Kunihiro IchinoseDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masaru KatoDepartment of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Ryo YanaiDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Yusuke MatsuoDepartment of Rheumatology, Tokyo Kyosai Hospital, Tokyo, Japan.
Ryo NishiokaDepartment of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Ryota OkazakiDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Tomoaki TakataDivision of Gastroenterology and Nephrology, Tottori University, Yonago, Japan.
Takafumi ItoDivision of Nephrology, Shimane University Hospital, Izumo, Shimane, Japan.
Mayuko MoriyamaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
Ayuko TakataniRheumatic Disease Center, Sasebo Chuo Hospital, Nagasaki, Japan.
Yoshia MiyawakiDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Toshiko Ito-IharaThe Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takashi KawaguchiDepartment of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Yutaka KawahitoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoshiki SekijimaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Shinshu University · JPKyoto Prefectural University of Medicine · JPJapanese Red Cross Society Kyoto Daini Hospital · JPShowa University · JPTottori University · JPChubu Rosai Hospital · JPHiroshima University Hospital · JPHokkaido University · JPJuntendo University · JPKagoshima University Hospital · JPKanazawa University · JPKyoto Katsura Hospital · JPKyoto University · JPNagasaki University · JPOkayama University · JPOsaka University of Pharmaceutical Sciences · JPSasebo City General Hospital · JPShimane University · JPShimane University Hospital · JPSt. Luke's International Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study investigated the characteristics of hypertrophic pachymeningitis (HP) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), using information from a multicenter study in Japan.

methodsWe analyzed the clinical information of 663 Asian patients with AAV (total AAV), including 558 patients with newly diagnosed AAV and 105 with relapsed AAV. Clinical findings were compared between patients with and without HP. To elucidate the relevant manifestations for HP development, multivariable logistic regression analyses were additionally performed.

resultsOf the patients with AAV (mean age, 70.2 ± 13.5 years), HP was noted in 30 (4.52%), including 20 (3.58%) with newly diagnosed AAV and 10 (9.52%) with relapsed AAV. Granulomatosis with polyangiitis (GPA) was classified in 50% of patients with HP. A higher prevalence of GPA was significantly observed in patients with HP than in those without HP in total AAV and newly diagnosed AAV (p < 0.001). In newly diagnosed AAV, serum proteinase 3 (PR3)-ANCA positivity was significantly higher in patients with HP than in those without HP (p = 0.030). Patients with HP significantly had ear, nose, and throat (ENT) (odds ratio [OR] 1.48, 95% confidence interval [CI] 1.03-2.14, p = 0.033) and mucous membrane/eye manifestations (OR 5.99, 95% CI 2.59-13.86, p < 0.0001) in total AAV. Moreover, they significantly had conductive hearing loss (OR 11.6, 95% CI 4.51-29.57, p < 0.0001) and sudden visual loss (OR 20.9, 95% CI 5.24-85.03, p < 0.0001).

conclusionGPA was predominantly observed in patients with HP. Furthermore, in newly diagnosed AAV, patients with HP showed significantly higher PR3-ANCA positivity than those without HP. The ear and eye manifestations may be implicated in HP development.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatosis with PolyangiitisMeningitisAgedAged, 80 and overAntibodies, Antineutrophil CytoplasmicCross-Sectional StudiesHumansHypertrophyJapanMiddle AgedMyeloblastinPeroxidaseRetrospective StudiesAntibodies, Antineutrophil CytoplasmicMyeloblastinPeroxidaseANCA-associated vasculitisAntineutrophil cytoplasmic antibodyConductive hearing lossEar, nose, and throatGranulomatosis with polyangiitisHypertrophic pachymeningitisMucous membranes/eyesSudden visual loss

Identifiers

PMID35999568
PMCPMC9396769
OpenAlexW4292702948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.